ASP Isotopes Inc. Reports $4.18 Million Revenue Growth and Strategic Acquisitions in Latest 10-Q

ASP Isotopes Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company generated total revenue of $4.18 million, a substantial increase from $1.1 million in the same period last year, primarily driven by the acquisition of Renergen, which contributed $0.6 million in revenue from liquefied natural gas (LNG) sales. The company also recognized $3.4 million from the sale of nuclear medical doses for PET and SPECT scanning, compared to $1.1 million in the prior year. Despite this revenue growth, ASP Isotopes incurred a net loss of $7.12 million, an improvement from a loss of $8.46 million in the previous year, attributed to increased operational expenses.

The company's operating expenses surged to $26.55 million from $8.28 million year-over-year, largely due to heightened research and development costs, which rose to $5.26 million from $1.53 million, and selling, general, and administrative expenses, which increased to $21.29 million from $6.75 million. The increase in expenses reflects the company's strategic initiatives, including the expansion of its workforce and operational capabilities following recent acquisitions. The total headcount has increased as the company ramps up its isotope production and commercialization efforts.

In terms of strategic developments, ASP Isotopes completed the acquisition of Renergen in January 2026, enhancing its position in the helium and LNG markets. The company also acquired Numed Diagnostics, LLC, and East Coast Nuclear Pharmacy, further diversifying its operations in the nuclear medicine sector. The acquisition of Renergen is particularly significant as it positions the company to capitalize on the growing demand for LNG and helium, with plans to commence helium liquefaction in the second half of 2026. Additionally, ASP Isotopes has initiated plans for further geographic expansion, targeting additional isotope enrichment plants in South Africa, Iceland, and the United States.

The company’s balance sheet reflects total assets of $587.67 million as of March 31, 2026, up from $498.02 million at the end of 2025. This increase is primarily due to the acquisition of Renergen and the associated assets. The company reported cash and cash equivalents of $207.35 million and short-term investments of $83.17 million, which management believes will be sufficient to fund operations for at least the next 12 months. However, ASP Isotopes acknowledges the need for ongoing capital to support its growth initiatives and may seek additional funding through equity or debt financing.

Looking ahead, ASP Isotopes remains focused on the commercialization of its enriched isotopes, with initial shipments of enriched Carbon-14 and Silicon-28 targeted for mid-2026. The company is also pursuing regulatory approvals for uranium enrichment, which could further enhance its market position. Despite the challenges associated with scaling operations and achieving profitability, ASP Isotopes is optimistic about its growth trajectory, driven by its strategic acquisitions and expanding product offerings in the nuclear medicine and energy sectors.